Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred W Sandrock

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Advances in Therapy|September 13, 2019
Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8Alfred W Sandrock, Wildon Farwell
The New England Journal of Medicine|December 19, 2009
Asymptomatic reactivation of JC virus in patients treated with natalizumabLeonid Gorelik, Susan Goelz, Alfred W Sandrock
Expert Opinion on Biological Therapy|September 9, 2008
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidenceRichard A Rudick, Sha Mi, Alfred W Sandrock
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
IEEE Transactions on Bio-Medical Engineering|August 1, 2002
Noninvasive detection of fibrillation potentials in skeletal muscleSteven P Keller, Alfred W Sandrock, Shai N Gozani
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Annals of Neurology|August 26, 2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick, Paul W O'Connor, Chris H Polman, et al.
CNS Drugs|March 20, 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying TherapiesAnthony T Reder, Diego Centonze, Maria L Naylor, et al.
JAMA Network Open|November 5, 2020
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis EpisodeTatiana Plavina, Carol M Singh, Dipen Sangurdekar, et al.
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Advances in Therapy|September 13, 2019
Comparisons Between Separately Conducted Clinical Trials: Letter to the Editor Regarding Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, et al. Adv Ther (2019) 36(5):1164-76. doi:10.1007/s12325-019-00923-8Alfred W Sandrock, Wildon Farwell
The New England Journal of Medicine|December 19, 2009
Asymptomatic reactivation of JC virus in patients treated with natalizumabLeonid Gorelik, Susan Goelz, Alfred W Sandrock
Expert Opinion on Biological Therapy|September 9, 2008
LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidenceRichard A Rudick, Sha Mi, Alfred W Sandrock
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
IEEE Transactions on Bio-Medical Engineering|August 1, 2002
Noninvasive detection of fibrillation potentials in skeletal muscleSteven P Keller, Alfred W Sandrock, Shai N Gozani
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Annals of Neurology|August 26, 2010
Assessment of JC virus DNA in blood and urine from natalizumab-treated patientsRichard A Rudick, Paul W O'Connor, Chris H Polman, et al.
CNS Drugs|March 20, 2021
COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying TherapiesAnthony T Reder, Diego Centonze, Maria L Naylor, et al.
JAMA Network Open|November 5, 2020
Association of Serum Neurofilament Light Levels With Long-term Brain Atrophy in Patients With a First Multiple Sclerosis EpisodeTatiana Plavina, Carol M Singh, Dipen Sangurdekar, et al.
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.
Pageof 2